A biobank-scale study shows that reduced CYP1A2 activity significantly increases pneumonia risk in patients treated with clozapine, alongside other well-known adverse effects. The findings reinforce the clinical value of pharmacogenetics in assessing antipsychotic safety and supporting risk-based monitoring. Read on to learn how emerging evidence can inform safer prescribing decisions.